By Dr. Vishal Saini, M.D., FAASM — Mid-West Center for Sleep Disorders
A patient told me recently that she'd finally "fixed" her insomnia. She'd been taking a CBD-CBN gummy marketed for sleep, every night for six months, and she was sleeping better. Then she asked the question that actually brought her in: "So why do I feel awful if I skip it, and why do I need two now when one used to work?"
That conversation contains almost everything you need to know about cannabinoids and sleep. There may be a real effect. There is almost certainly a tolerance problem. And the product she trusted had never been tested for either — because in the world of over-the-counter cannabinoid sleep aids, the marketing is years ahead of the science.
Cannabinoid sleep products are now everywhere: gummies, tinctures, vapes, and capsules promising deeper sleep and easier nights, sold in dispensaries, gas stations, and wellness shops. People are voting with their wallets — by one estimate, more than one in ten US adults has used CBD for a therapeutic reason (Hsu et al., JAMA, 2026, PMID 41296368). So it's worth asking, carefully and without either hype or reflexive dismissal: does any of this actually work, and what should you know before you try it?
A Quick Map of What's in These Products
"Cannabinoid" is not one thing, and the differences matter enormously for sleep.
THC (delta-9-tetrahydrocannabinol) is the psychoactive compound — the one that produces a "high." It's the cannabinoid with the most direct, measurable effects on sleep, both good and bad. CBD (cannabidiol) is non-intoxicating and is the main ingredient in most "wellness" sleep products; confusingly, its effect on sleep is dose-dependent and not always sedating. CBN (cannabinol) is a minor cannabinoid heavily marketed as "the sleep cannabinoid," despite having almost no rigorous human evidence behind that claim. And then there are prescription cannabinoids — dronabinol and nabilone (synthetic THC) — which are FDA-approved for chemotherapy nausea and AIDS-related appetite loss, not for sleep.
The single most important thing to understand is this: the compound doing the heavy lifting for sleep is THC, not the CBD that most people think they're buying for its "safety."
What the Evidence Actually Shows
Let me give you the honest state of the research, because it's more nuanced than either the supplement industry or the skeptics will tell you.
The most recent and most relevant synthesis is a 2025 systematic review and meta-analysis in Sleep Medicine Reviews (da Silva et al., 2025, PMID 40929927). Pooling six randomized controlled trials and 1,077 patients, the authors found that cannabinoids did significantly improve self-reported sleep quality compared with placebo (standardized mean difference 0.53), and the effect was a bit larger in people who actually had insomnia or poor sleep (SMD 0.60). That's a real, moderate signal — and it's why I don't dismiss this category outright.
But two findings inside that same analysis are the whole story. First, the effect was driven almost entirely by non-CBD formulations — products containing THC (SMD 0.82). CBD-only products showed no significant effect on sleep at all (SMD 0.13). Second, the heterogeneity between studies was enormous (statistically, around 88%), meaning the trials were all over the map in design, dose, and result. A moderate average effect built on wildly inconsistent studies is a hypothesis worth pursuing, not a settled fact.
"The honest headline is awkward for the wellness industry: the cannabinoid that seems to help sleep is the one that gets you high, and the one most people are buying for sleep — CBD by itself — performs about like placebo in the controlled trials." — Dr. Vishal Saini
That picture lines up with the broader medical consensus. A comprehensive 2026 review in JAMA concluded flatly that evidence from randomized trials "does not support the use of cannabis or cannabinoids for most conditions for which it is promoted, such as acute pain and insomnia" (Hsu et al., 2026, PMID 41296368). Some reviews of medical cannabis are more optimistic — a 2026 systematic review in nurse-practitioner literature found medical cannabis may reduce sleep disturbance and daytime sleepiness while increasing total sleep time (Begazo et al., J Am Assoc Nurse Pract, 2026, PMID 42207928) — but these draw heavily on lower-quality and observational data, which is exactly where placebo and expectation effects run strongest.
Where it gets genuinely interesting is when you stop asking people how they think they slept and actually measure their brain overnight.
The Counterintuitive Part: What Cannabinoids Do to Your Sleep Architecture
Here is a study that every person reaching for a THC sleep product should know about.
In a 2026 pilot randomized controlled trial, Australian researchers gave 20 patients with diagnosed insomnia a single oral dose of 10 mg THC plus 200 mg CBD — a combination very similar to many commercial products — and measured their sleep with 256-channel high-density EEG (Suraev et al., Journal of Sleep Research, 2026, PMID 40631525). The results were not what the marketing would predict.
The cannabinoid dose decreased total sleep time by about 24 minutes compared with placebo. It dramatically suppressed REM sleep — cutting it by nearly 34 minutes and pushing REM onset more than an hour later into the night. In other words, a product sold to improve sleep measurably reduced how long these patients slept and reshaped the architecture of the night, mostly by stripping out REM.
This is consistent with decades of sleep physiology: THC tends to shorten the time it takes to fall asleep at first, but it also reliably suppresses REM sleep, the dream-rich stage tied to emotional processing and memory consolidation. The subjective experience of "knocking out" faster is real. What it costs you in REM is invisible in the moment — which is precisely the problem.
"Falling asleep faster and sleeping well are not the same thing. THC is reasonably good at the first and quietly works against the second. Patients feel the sedation and never feel the missing REM." — Dr. Vishal Saini
To be fair, that same trial found some reassuring news on next-day safety: there was no measurable impairment in objective alertness, cognition, or even simulated driving performance the next morning (at least nine hours after the dose), just a small bump in self-reported sleepiness. And not every cannabinoid study points the same way — a 2025 crossover trial of specific CBD-and-terpene formulations reported that certain ratios increased deep sleep and REM in some people with insomnia (Wang et al., J Clin Sleep Med, 2025, PMID 39167421). The truth is that "cannabinoids" is too broad a category for one verdict, and the dose, the ratio, and the person all change the answer.
What to Realistically Expect If You Try One
Patients deserve straight talk about what these products tend to do, so here is what the evidence and clinical experience suggest.
You may fall asleep faster, especially with a THC-containing product, and you may feel subjectively that your sleep is better. That feeling is partly real and partly expectation — and it matters, because how rested you feel is part of what we're treating. CBD-only products, by contrast, are likely to do very little for sleep beyond what a placebo would do, despite being the most heavily marketed "sleep" option.
Expect the effect to fade. This is the part that catches people off guard. With regular THC use, tolerance develops, which is why my patient went from one gummy to two. And when you stop, the REM your brain was suppressing tends to come roaring back — a rebound that shows up as vivid or unsettling dreams, restlessness, and worse sleep for several nights. That withdrawal-driven insomnia then feels like proof that you "need" the product, when it's actually a sign of dependence forming. It's the same trap we see with alcohol as a sleep aid, and it's the reason cannabinoids make a poor long-term insomnia strategy even when they help at first.
Do not expect a treated cause. Insomnia is usually a symptom — of stress, depression, circadian misalignment, an untreated breathing disorder, or simply conditioned hyperarousal. A gummy that sedates you doesn't address any of those, and the most effective, durable treatment for chronic insomnia remains cognitive behavioral therapy for insomnia (CBT-I), not any pill or supplement.
The Cautions That Rarely Make the Label
This is where I want to be most direct, because the casual, "it's just a plant" framing around these products obscures some real risks.
You often don't know what you're taking. The cannabinoid supplement market is poorly regulated, and product contents frequently don't match the label. In a landmark analysis of CBD extracts sold online, nearly 70% were inaccurately labeled, and about one in five contained THC that wasn't disclosed (Bonn-Miller et al., JAMA, 2017, PMID 29114823). For someone subject to workplace drug testing, in recovery, pregnant, or simply trying to avoid intoxication, undisclosed THC is not a small problem.
Cannabis use disorder is real and common. Among people using cannabis medically, roughly 29% meet criteria for cannabis use disorder (Hsu et al., 2026, PMID 41296368). Using a substance nightly, specifically to be able to sleep, is one of the classic on-ramps to that dependence.
Higher-potency products carry mental-health and cardiovascular risk. The same JAMA review found high-potency cannabis associated with markedly higher rates of psychotic symptoms (12.4% vs 7.1%) and generalized anxiety (19.1% vs 11.6%) compared with lower-potency use, and daily inhaled use associated with increased rates of heart attack and stroke (Hsu et al., 2026, PMID 41296368). These are not reasons for panic, but they are reasons to take dose and frequency seriously.
Some people should not use these products at all. That list includes people who are pregnant or breastfeeding, those with a personal or family history of psychosis or schizophrenia, people with significant heart disease, and anyone combining them with alcohol or other sedatives like benzodiazepines or opioids — a combination that compounds respiratory and cognitive depression. And you should not drive or operate machinery under the influence, full stop.
If you snore or might have sleep apnea, this matters even more. Sedating yourself into sleep can blunt the arousals that protect your airway, and it can mask the daytime sleepiness that would otherwise prompt a diagnosis. The American Academy of Sleep Medicine has formally taken the position that medical cannabis and its synthetic extracts should not be used to treat obstructive sleep apnea, citing unreliable dosing and insufficient evidence of safety and effectiveness (Ramar et al., J Clin Sleep Med, 2018, PMID 29609727). Using a cannabinoid to paper over the symptoms of undiagnosed apnea is one of the scenarios that worries me most.
"My concern isn't that someone tries a sleep gummy. It's that they use it for a year to silence a symptom, develop a dependence on it, and never find out that the real problem was apnea, depression, or a circadian rhythm that a few targeted changes could have fixed." — Dr. Vishal Saini
What This Means Clinically — and Questions Worth Asking
If you're considering or already using a cannabinoid for sleep, a few practical principles:
Be honest with your physician about it. Cannabinoids interact with other medications — they can affect how your liver processes certain drugs, including some blood thinners and seizure medications — and your clinician can't account for what they don't know you're taking.
Treat persistent insomnia as a reason for evaluation, not just self-medication. If you've needed something to sleep most nights for more than a few weeks, that's a clinical signal. The questions worth bringing to a visit: Could something treatable be driving this — apnea, restless legs, depression, thyroid, a medication, my schedule? Have I actually tried CBT-I, which outperforms medication for long-term results? And if I'm using a cannabinoid, what's my plan to taper rather than escalate?
If you do use one, lower potency and the lowest effective dose are safer, occasional use beats nightly use, and a product with third-party testing and a certificate of analysis is far preferable to an unverified one. These are harm-reduction steps, not endorsements.
What the Research Still Hasn't Answered
In the spirit of intellectual honesty: we don't yet have large, long-term, high-quality trials of standardized cannabinoid products for chronic insomnia, and we badly need them. We don't know the optimal cannabinoid ratios, doses, or timing, and the wide variation between the existing studies (da Silva et al., 2025, PMID 40929927) reflects that gap. We don't have good data on the long-term consequences of chronic REM suppression from nightly THC. And we don't have nearly enough study of CBN specifically, despite it being marketed as the sleep cannabinoid. Anyone who tells you the science is settled — in either direction — is overstating it. What we can say is that the burden of proof has not yet been met for cannabinoids as a first-line insomnia treatment.
The Bottom Line
The evidence for cannabinoid sleep products is real but modest, and it points somewhere uncomfortable: the effect is driven by THC, not the CBD most people are buying, and even THC tends to help you fall asleep while quietly suppressing REM and breeding tolerance and dependence over time. They can blunt a symptom for a night; they don't treat the cause, and they carry real risks around regulation, dependence, mental health, and masked sleep apnea. If you sleep poorly enough to medicate it most nights, the most evidence-based move isn't a stronger gummy — it's finding out why you're not sleeping in the first place.
Dr. Vishal Saini, M.D., FAASM is the Research & Medical Director at Mid-West Center for Sleep Disorders and Principal Investigator on multiple clinical trials in sleep medicine across Michigan. He evaluates and treats insomnia, sleep apnea, narcolepsy, and complex hypersomnia disorders in Lansing, Traverse City, and Eaton Rapids.
Relying on something to fall asleep most nights? Let's find out why — and treat it properly.
Book a Consultation → | (517) 887-6733
References: da Silva GHS, Barbosa EC, de Lima FR, et al. Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: a systematic review and meta-analysis. Sleep Med Rev 2025 (PMID 40929927); Hsu M, Shah A, Jordan A, Gold MS, Hill KP. Therapeutic use of cannabis and cannabinoids: a review. JAMA 2026 (PMID 41296368); Suraev A, McGregor IS, McCartney D, et al. Acute effects of oral cannabinoids on sleep and high-density EEG in insomnia: a pilot RCT. J Sleep Res 2026 (PMID 40631525); Wang M, Faust M, Abbott S, et al. Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. J Clin Sleep Med 2025 (PMID 39167421); Begazo K, Laing K, Mineo A, et al. Medical cannabis for treatment of insomnia in adults: a systematic review and meta-analysis. J Am Assoc Nurse Pract 2026 (PMID 42207928); Bonn-Miller MO, Loflin MJE, Thomas BF, et al. Labeling accuracy of cannabidiol extracts sold online. JAMA 2017 (PMID 29114823); Ramar K, Rosen IM, Kirsch DB, et al. Medical cannabis and the treatment of obstructive sleep apnea: an AASM position statement. J Clin Sleep Med 2018 (PMID 29609727).